European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Triple negative breast cancer (TNBC) is an aggressive and rapidly growing subtype of breast cancer characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) expression, rendering it resistant to targeted therapies. In the absence of molecular targets, the pathogenesis of TNBC is not well understood and many studies are focused towards identifying the pathways and molecular signatures associated with the initiation and progression of TNBC. Heat shock proteins emerged as key players in the tumorigenic pathways of several types of cancer including TNBC. In the present study, paraffinembedded tumor tissues of 66 Jordanian TNBC patients were analyzed, retrospectively, by immunohistochemistry to investigate the expression of HSP90, HSP70, HSP60, and HSP27 in Jordanian TNBC patients. The expression of the aforementioned markers was also examined using disease-free survival (DFS) along with a variety of clinical and pathological characteristics such as age, stage/grade of tumor, and nodal involvement. Positive expression of HSP90, HSP60, HSP27, and HSP70 was shown in 89%, 79%, 76%, and 40% of the cases analyzed, respectively. HSP60 positive expression was found to be significantly correlated with advanced stage (pT3/pT4) of the tumor (p = 0.05), nodal involvement (p = 0.03), and older age of patients (p = 0.03). Among the clinical and pathological variables analyzed in the present study, it was found that advanced stage (pT3/pT4) of the tumor and older age of the patients were significantly associated with worse DFS (p = 0.001 and 0.02, respectively). Additionally, positive expression of HSP60 showed to be correlated with worse DFS (p = 0.05). This study highlights the importance of HSP60 as a marker of poor prognosis in TNBC patients.